Xingtai will treat new coronavirus drugs into medical insurance

January 16, 2023January 16, 2023

Read Time:1 Minute, 28 Second

From Xingtai City Medical Insurance Bureau was informed that, in the face of the new situation and new tasks of prevention and control of the new crown virus infection, Xingtai City from this month will be the new crown treatment-related drugs into the scope of medical insurance reimbursement, to effectively meet the needs of patients for medical care and medication, to reduce the burden of patients’ medical costs.

According to the introduction, in accordance with the relevant national requirements, nearly 100 kinds of new crown drugs in line with the treatment plan are included in the scope of medical insurance reimbursement in Xingtai, including nematovir tablets / ritonavir tablets (paxlovid), ambavir monoclonal injection, romisilvir monoclonal injection, Azulfidine tablets, etc.

According to the relevant policy, there is no starting and capping line for reimbursement of outpatient and emergency medical expenses related to the treatment of novel coronavirus infection incurred by the insured patients at the second level or below medical institutions in Xingtai City, and the reimbursement rate is 70%.

The new coronavirus treatment drugs in the new coronavirus infection treatment plan that are not in the basic medical insurance catalog are temporarily included in the scope of payment of medical insurance funds.

To facilitate the purchase of drugs, the medical insurance department has broadened the scope of use of medical insurance personal accounts, participants in the city’s designated retail pharmacies, can be used to purchase medical insurance personal accounts for new coronavirus treatment-related drugs.

For clinical necessity, the provincial medical drugs centralized procurement platform no enterprise supply of drugs, medical institutions can search for manufacturers offline, and enterprises to agree on prices after the first purchase, timely in the provincial medical drugs centralized procurement platform to fill the purchase order information.